Ann: Primary Endpoint Met in Phase II Soft Tissue Sarcoma Trial, page-3

The novel combination significantly exceeded the study’s prespecified median of 35%tumour hyalinization/fibrosis versus 15% for historical data from radiotherapy alone in patients with resectablesoft tissue sarcoma (STS).Tumour hyalinization/fibrosis is an early surrogate endpoint at the time of surgical resection that has beenassociated with improved overall survival and recurrence-free survival for STS patients.1,2

The trial’s investigatorsat the Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO) in Warsaw, the nationalreference centre for STS in Poland, plan to present detailed results from the study at a future medical meeting.Katarzyna Kozak, M.D., Ph.D., and Paweł Sobczuk, M.D., Ph.D., medical oncologists at the Department of SoftTissue/Bone Sarcoma and Melanoma at MSCNRIO and the trial’s principal investigators, said: “It is veryencouraging to see the chemotherapy-free combination with efti far exceed the ambitious target we initially setfor the trial's primary endpoint in resectable soft tissue sarcoma

Ill take that language in all media releases from now on please.